MDRNA Acquires Cequent Pharmaceuticals for $46,000,000

  • Feed Type
  • Date
  • Company Name
    Cequent Pharmaceuticals
  • Mailing Address
    One Kendall Square Building 700 First Floor Cambridge, MA 02139
  • Company Description
    Cequent Pharmaceuticals, Inc. is an early-stage biopharmaceutical company developing new clinically compatible therapies based on RNA interference (RNAi). Cequent is focusing its efforts on the pre-clinical development of products to treat gastrointestinal diseases, including familial polyposis, inflammatory bowel disease and colon cancer.
  • Website
  • Transaction Type
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
  • M&A Terms
    MDRNA will acquire Cequent Pharmaceuticals in an all-stock deal worth $46 million.

Trending on Xconomy